Skip to content
Open access

Multi‐Omics Integration Identifies a Five‐Gene Metabolic Signature With Experimental Validation in Clear Cell Renal Cell Carcinoma

Sep 2026 · Cancer Reports · Vol 9 · 0 citations · 37 references
Medicine

TL;DR

This study aims to systematically decipher the metabolic‐immune interplay in ccRCC through multi‐omics integration, with the goal of identifying robust prognostic biomarkers and actionable therapeutic vulnerabilities.

Abstract

Clear cell renal cell carcinoma (ccRCC) is hallmarked by profound metabolic reprogramming; however, its intricate crosstalk with the tumor immune microenvironment (TIME) and its clinical ramifications remain inadequately elucidated. This study aims to systematically decipher the metabolic‐immune interplay in ccRCC through multi‐omics integration, with the goal of identifying robust prognostic biomarkers and actionable therapeutic vulnerabilities.

Read PDF

Similar papers

Open access Sep 2026

FABP4 characterizes metabolic–immune interactions and serves as a prognostic biomarker across gynecologic malignancies: a multi-omics integrative analysis

Highlights • FABP4 is broadly downregulated across five gynecologic malignancies.• Promoter hypermethylation is associated with reduced FABP4 expression.• High FABP4 marks poor ovarian/cervical but favorable endometrial outcomes.• Single-cell and spatial data link stromal FABP4 to metabolic–immune crosstalk.• FABP4 kno...

Fang-Fang Chen, Li-Feng Dong, Sai-Sa Zhu et al. · 0 citations
Open access Sep 2026

Acrylamide-associated gastric cancer progression involves RRM2-related nucleotide metabolic dysregulation and immune evasion

Highlights • RRM2 identified as acrylamide-associated hub gene in gastric cancer.• Multi-cohort integration reveals nucleotide metabolism dysregulation.• Machine learning prognostic model stratifies GC risk groups.• Single-cell analysis uncovers immune evasion signaling networks.• Experimental validation confirms RRM2...

Pei-Ru Si, Tian-Long Zhang, Xue-Feng Lv · 0 citations
Open access Aug 2026

Identification of a three-gene prognostic signature associated with tumor immune characteristics in lung adenocarcinoma: A comprehensive analysis of multi-omics data

Highlights ● Multi-omics analysis identifies a robust three-gene prognostic signature for LUAD.● The signature stratifies patients by survival and tumor immune characteristics.● High-risk tumors display proliferative programs and immunotherapy-related features.● The model predicts differential responsiveness to immune...

Huangkai Zhu, Yannan Fang, Minglei Yang et al. · 0 citations
Open access Aug 2026

Integration of single-cell transcriptomics and genomic mutation analysis identifies an immunotherapy-resistant tumor subcluster and validates ARNTL2 as a malignant driver in lung adenocarcinoma

Single-cell sequencing reveals resistance-linked malignant subcluster in LUAD, confirming oncogenic role and CoxBoost + survivalSVM model achieves optimal C-index of 0.686 across seven cohorts.

Z. Qiu, Hui Zhao, Qiong Lyu et al. · 0 citations
Open access Sep 2026

Integrated single-cell and bulk transcriptomic analysis reveals an epithelial cell-derived prognostic and immunotherapeutic signature with ADAM12 as a key functional regulator in non-small cell lung cancer

Highlights • Single-cell transcriptomics reveals epithelial heterogeneity shaping NSCLC immunity.• A 101-algorithm ML framework constructs a Prognostic and Immunotherapeutic Signature.• PIS stratifies NSCLC patients by prognosis and immune checkpoint blockade response.• ADAM12 inhibition enhances anti-PD-1 efficacy in...

Hai-Lin Liu, Jun-Jie Yu, Yan-Tao Jiang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.